Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy presents an in-depth and up-to-date compilation of research on isocitrate dehydrogenase as drug target to be used as a sensitizing agent in chemotherapy. The book brings a combination of medicinal, biological and chemical points-of-view to fully cover the subject. It discusses topics such as IDH place in cellular metabolism, mutant IDH as drug target, mono- and poli-therapies based on IDH1/2 inhibitors, and IDH1/2 inhibitors in leukemia, gliomas and other brain tumors, and potential importance in gastrointestinal cancers. Additionally, it discusses isocitrate dehydrogenases as target for theranostics, therapeutic strategies and future perspectives.
This is a valuable resource for cancer researchers, oncologists and members of the biomedical field who are interested to learn more about IDH inhibitors and their potential as sensitizing agents for chemotherapy.
This is a valuable resource for cancer researchers, oncologists and members of the biomedical field who are interested to learn more about IDH inhibitors and their potential as sensitizing agents for chemotherapy.
Table of Contents
1. Isocitrate dehydrogenase and its place in cellular metabolism2. Wild type and mutant IDH as drug target
3. Holy grail of combination therapy? Possibilities and limitations of mono- and poli-therapies based on IDH1/2 inhibitors
4. Two faced IDH. The good and bad in prognosis
5. Inhibitors of IDH1/2 in leukemias
6. Inhibitors of IDH1/2 in gliomas and other brain tumors
7. Potential importance of IDH in gastrointestinal cancers
8. Isocitrate dehydrogenases as target for theranostics
9. Resistance emerging and therapeutic strategies
10. Challenges and future perspectives
